| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8305209 | Biochimie | 2014 | 8 Pages |
Abstract
This review will summarize the current knowledge about MSCs engineered to express different suicide genes (cytosine deaminase, thymidine kinase, carboxylesterase, cytochrome P450) to elicit a significant antitumor response against brain tumors, ovarian, hepatocellular, pancreatic, renal or medullary thyroid carcinomas, breast or prostate cancer and pulmonary metastases. The potential side effects of these MSC-based tumor therapies will also be considered to highlight certain aspects that need to be improved prior to clinical use.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Ikrame Amara, Walid Touati, Philippe Beaune, Isabelle de Waziers,